€404.55
Your prediction
Vertex Pharmaceuticals Inc. Stock
Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Vertex Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 1.340% | -2.294% | 7.237% | -11.564% | 3.281% | 47.889% | 136.690% |
| Incyte Corp. | -0.560% | 0.986% | -1.826% | 26.545% | 2.114% | 16.610% | 29.362% |
| Regeneron Pharmaceuticals Inc. | -0.690% | -2.247% | 5.589% | -0.241% | -0.302% | -6.544% | 70.281% |
| IQVIA Holdings Inc. | -2.430% | 0.000% | -29.549% | -23.924% | -27.214% | -31.986% | -9.904% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When evaluating the financial position of Vertex Pharmaceuticals Inc. (symbol: VRTX), it is evident that the company exhibits robust financial health, especially for a player in the Biotechnology & Medical Research sector. As observed from the provided financial statements, Vertex demonstrates strong revenue growth, impressive profitability, and significant cash reserves. This overall positive trend is accompanied by notable investment in research and development, which is critical for sustaining innovation in the biotech field. However, like any investment, a deeper dive into the various financial metrics is essential to identify both advantages and drawbacks.
Strong Revenue Generation: Vertex reported a total revenue of approximately $9.87 billion for 2023, showcasing healthy growth compared to previous years. The quarterly revenue growth rate of 13.3% indicates consistent demand for its products, which is promising for future sales and market expansion.
Impressive Profit Margins: The profit margin stands at around 39.5%, highlighting Vertex's ability to convert sales into profits effectively. Coupled with an operating margin of 45.2%, it reflects efficient management of operational expenses relative to revenue.
Comments
News
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices
Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics (NASDAQ: CRSP), is the real buy for long-term investors.
Shares of Vertex, a biotech
Why Vertex Stock Zoomed Almost 6% Higher on Thursday
Investors were snapping up shares of fintech stock Vertex (NASDAQ: VERX) on Thursday. That followed a rather glowing research update from an analyst at a prominent investment bank. With that in its
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory.
The
